17,261 trials
Treatment Resistant Depression
Primary: Hamilton Rating Scale for Depression - 6 Items — 12.5555556; 12.7500000; 12.5909091; 12.6315789 units on a scale — p=0.14
Ulcerative Colitis
Primary: Relapse Free Survival Week 17-48 — 12; 12 Participants
Head and Neck Cancer
Primary: Progression-Free Survival (PFS) — 1.9; 2.0 months — p=0.0667
Relapsed Acute Leukemia · Refractory Acute Leukemia
Primary: Number of Participants With Dose Limiting Toxicity in Phase I — 0; 0; 0 Participants
Advanced Breast Cancer
Primary: 16-week Progression-free Survival (PFS) Rate — 44.8 percentage of population
Glioblastoma
Primary: Number of Participants With Change in Peritumoral Enhancement/Edema — 1; 2 Participants
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms
Primary: Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer — 3.3; 0; 3.6 percentage of participants
Cystic Fibrosis
Primary: Safety as Determined by Adverse Events (AEs) — 30; 8; 7; 15 participants
Chronic Hepatitis D Infection
Primary: Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy — 0; 0; 0 Participants
Cystic Fibrosis
Primary: PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 5; 15; 13 Participants
Cocaine Dependence
Primary: Cocaine Treatment Outcome — 0; 14; 13 positive drug screens
Hypogonadism
Primary: Cmax-am for Oral TU Across Breakfast With Varying Fat Content — 250.7; 334.7; 529.7; 506.0 ng/dL
Prostate Cancer
Primary: Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months — -0.75; 1.55; 10.21; 4.89 Relative % difference
Bone Marrow Failure Syndromes · Immunodeficiencies · Immune Dysregulation Syndromes
Primary: Number of Participants With Engraftment — 2 Participants
Rheumatoid Arthritis
Primary: Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4 — 1.736; 2.105 fold rise